"One of the advantages of this system for critical care is that all of the RAMP cardiac tests correlate to the same tests on larger analyzers in the lab, such as the cobas 6000 series," said Ken Levy, Director of Strategic Business Development for Roche Diagnostics' Point of Care division. "This way, physicians can be confident that the results they get in the ER and in the lab are consistent, so they can provide better treatment to the patient."
Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007, sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested more than 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.
About Response Biomedical
Response Biomedical develops, manufactures and markets rapid on-site
diagnostic tests for use with its RAMP Platform for clinical and
|SOURCE Roche Diagnostics|
Copyright©2008 PR Newswire.
All rights reserved